Navigation Links
Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS
Date:12/1/2011

PITTSBURGH, Dec. 1, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited (formerly Matrix Laboratories Limited) has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Atazanavir Sulfate and Ritonavir Tablets, 300 mg/100 mg.

This product is the first heat-stable, fixed-dose combination of Atazanavir Sulfate and Ritonavir, an antiretroviral (ARV) used to treat HIV/AIDS. It also has been "prequalified" by the World Health Organization (WHO) as a second-line treatment option and can be used in combination with other ARVs for the treatment of HIV/AIDS. It will be eligible for purchase outside the U.S. in certain developing countries; it also will be a significant addition to Mylan's ARV portfolio in India, which is expected to become available during the second quarter of 2012.

Mylan President Heather Bresch said: "The approval of this fixed dose product is a groundbreaking development for the treatment of second-line HIV/AIDS patients. For the first time, it makes available a generic antiretroviral (ARV) drug with Atazanavir Sulfate and Ritonavir in a fixed-dose combination tablet. This 'combo' helps to facilitate treatment compliance for HIV/AIDS patients by providing a convenient, once-a-day dosing option, while reducing the cost of treatment for patients. The approval is representative of Mylan's continued commitment to providing critical life-saving therapies to people living with HIV/AIDS around the world."

The FDA's tentative approval through PEPFAR signifies that Mylan's product meets all of the agency's manufacturing quality, safety and efficacy standards. Atazanavir and Ritonavir are the generic versions of Bristol-Myers Squibb's Reyataz® and Abbott Laboratories' Norvir&
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Launches Generic Version of Caduet® Tablets
2. Mylan Confirms First-to-File Patent Challenge Relating to Generess™ Fe
3. Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
4. Mylan Receives Approval for Generic Version of Zinecard® for Injection
5. Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot®
6. Mylan Successfully Upsizes and Completes Refinancing of Credit Facility
7. Mylan Applauds Obama Administrations Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
8. Mylan to Acquire Pfizer Respiratory Delivery Platform
9. Mylan Receives Approval for Generic Version of MS Contin® Tablets
10. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
11. Mylans Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015  Hill-Rom Holdings, Inc. (NYSE: ... Seng has been elected to its Board of ... Residence for Covidien, as well as President of Covidien,s ... Peripheral Vascular from 2010 to 2012. Ms. ... acquisition of ev3 Incorporated, where she was a founding ...
(Date:3/4/2015)... March 4, 2015 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China, today announced ... year 2014. Fourth Quarter 2014 Financial ... quarter of 2014 increased by 36.2%, or 36.8% excluding ... $58.0 million from $42.6 million in the same quarter ...
(Date:3/4/2015)... , March 4, 2015 Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... will ring The Opening Bell ® of the ... 2015. Asterias began trading as an NYSE MKT listed ... York Stock Exchange is a trusted partner to Asterias ...
Breaking Medicine Technology:Hill-Rom Elects Stacy Enxing Seng to its Board of Directors 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
... , LACHEN, Switzerland , Jan. ... of plasma products in the world, today announced that it has received ... Food and Drug Administration (FDA). The approval was granted for the ... bleeding episodes in patients with severe von Willebrand disease (VWD) as well ...
... , SUNNYVALE, Calif. , Jan. 13 ... of radiosurgery, today announced that it will report results for its fiscal second ... 4, 2010 after the market closes. , A conference call to review ... EST and will be hosted by Euan S. Thomson , Ph.D., ...
Cached Medicine Technology:Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 5Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 6Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010 2Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010 3
(Date:3/4/2015)... (PRWEB) March 04, 2015 The ... subjectivity in density assessment and help improve breast ... numerous abstracts accepted for presentation at the European ... Ten abstracts - eight posters and 2 ... Solutions’ automated breast density and quantitative breast imaging ...
(Date:3/4/2015)... Starting February 2015, Dr. Joseph King ... at their new location in Surrey. , In addition ... Dr. Gabriel Chu also provide comprehensive ophthalmology services, including ... Fraser Valley Cataract and Laser (FVCL). This state of ... of Physicians and Surgeons of British Columbia. Fraser Valley ...
(Date:3/4/2015)... State officials have awarded $82,500 to ... Public Health at Georgia State University, to support the ... Georgia’s Division of Family and Children Services (DFCS) as ... Center. , The 1-800-CHILDREN Helpline is a top ... referral services that promote the wellbeing of children while ...
(Date:3/4/2015)... 04, 2015 Organic Valley, the nation’s largest ... announced its cause campaign to Save the Bros, http://savethebros.com/ ... making a difference to Bros everywhere. To date, the ... Facebook. The video was named Adweek’s best commercial of ... Mashable and Digiday, among other media outlets. , “We ...
(Date:3/4/2015)... March 04, 2015 SIGVARIS ... technology and their first compression therapy collection designed exclusively ... this collection, SIGVARIS USA is proud to announce the ... product line. , Constructed from a unique, extremely fine ... in mind. These socks and thigh-highs offer a tailored ...
Breaking Medicine News(10 mins):Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:King LASIK relocates to Surrey, British Columbia 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2
... The holiday season is here,which for most Americans ... homes bustling with family and friends. All of this ... risk for contracting,viruses, particularly influenza. Maxim Health Systems is ... have not already done so, not only,to protect themselves ...
... FRANCISCO, Calif., Oct. 29 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... president and chief operating officer, will present,a company overview ... 3 at 3:20 p.m. EST at The Waldorf Astoria ... audio webcast or the subsequent archived recording,log on to ...
... Oct. 29 SkinMedica, Inc.,s 45 sales,consultants from ... to,take part in a spectacular sales meeting at ... joined by an additional 40 employees,from sales, marketing, ... operations. CEO Mary Fisher kicked off the meeting,with ...
... tesamorelin, a Phase III compound being investigated ... patients with lipodystrophy -- Theratechnologies to receive up ... in the US -- Merck KGaA, Darmstadt, Germany, of which ... equity investment in Theratechnologies -- EMD Serono acquires option to ...
... -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: ... company that develops, manufactures and markets advanced ... will be attending the,Credit Suisse Asian Healthcare ... Location: Beijing, China, China Medical Technologies, ...
... makes a Sustainable Transition with SafePath,s ADA Approved, ... CHICO, Calif., Oct. 29 For nearly 40 ... is not just,a decision of who to vote ... at all.,Despite federal and state regulations mandating compliance ...
Cached Medicine News:Health News:Give the Gift of Good Health This Holiday Season - Remind Friends and Family to Get a Flu Shot 2Health News:Give the Gift of Good Health This Holiday Season - Remind Friends and Family to Get a Flu Shot 3Health News:SkinMedica Hosts Aesthetics Division National Sales Meeting 2Health News:SkinMedica Hosts Aesthetics Division National Sales Meeting 3Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 2Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 3Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 4Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 5Health News:SafePath(TM) Products Provides Universal Access for Ohio Voters 2
... is a 2-megapixel, 12-bit FireWire digital camera. Comes complete ... effortlessly. Imaging has never been this easy! Choose from ... CCD - 2/3" Color Bit Depth ... - 500 microseconds - 60 seconds Hardware ...
... camera incorporates a Progressive Scan 1/2" CCD with ... x 960 (V) SXGA. Whats more the XCD-SX910CR ... called a "Bayer filter") and outputs the "raw ... to be converted to a color image on ...
... monochrome " 1.3 Megapixel FireWire camera suitable ... to simplify real-time uncompressed video display and ... video and digital still-image quality in an ... ideal for industrial inspection tasks involving brightfield ...
... GT-CAPTURE digital camera photomicrographic system can be ... as Olympus, Leica, Nikon, and Zeiss, making ... images over the Internet easy and fast. ... performance-proven Nikkor lens. The system records photomicrographic ...
Medicine Products: